mvp-s,pembrolizumab
merck,imv inc
['pesco', 'gyn', 'maveropepimut', 'pembro']
oral abstracts #asco22 #gyncsm pembrolizumab, maveropepimut-s, &amp; low-dose cyclophosphamide in adv epithelial oc: phase 1 expansion cohort of pesco trial.
*ae injection site reaction
* drug well tolerated
*response seen to this combo
further study needed 
#ovca survivor; research advocate; author; co-moderator #gyncsm chat;  #ASCO22 Feature Voice  COI: https://t.co/AUF1EprNVt Opinions are my own.